Table 2.
Significant predictors of clinical worsening during follow-up intervals in univariate repeated measures logistic regression model
| Positive Predictors of Clinical Worsening | OR (95% CI) | P Value |
|---|---|---|
| Female | 1.27 (1.13–1.43)* | 0.0002* |
| Age | 1.03 (1.02–1.05)* | <0.0001* |
| Race | ||
| Black vs. White | 0.95 (0.80–1.13) | 0.242 |
| Other vs. White | 0.81 (0.64–1.02) | |
| Black vs. Other | 1.18 (0.89–1.56) | |
| Migraine with aura | 1.01 (0.88–1.16) | 0.951 |
| Status migrainosus at visit A | 1.47 (1.28–1.68)* | <0.0001* |
| Number of months with headaches at initial visit | 1.00 (0.99–1.00) | 0.175 |
| BMI category at visit A | 0.951 | |
| Overweight vs. Normal/underweight | 0.97 (0.85–1.12) | |
| Obese vs. Normal/underweight | 1.01 (0.88–1.15) | |
| Obese vs. Overweight | 1.03 (0.87–1.22) | |
| Recommended preventive treatment type at visit A | <0.0001* | |
| Nutraceutical alone vs. None | 1.22 (0.98–1.52) | |
| Pharmaceutical alone vs. None | 0.58 (0.50–0.68)* | |
| Nutraceutical plus Pharmaceutical vs. None | 0.84 (0.72–0.97)* | |
| Pharmaceutical alone vs. Nutraceutical alone | 0.48 (0.39–0.58)* | |
| Nutraceutical plus pharmaceutical vs Nutraceutical alone | 0.69 (0.57–0.83)* | |
| Nutraceutical plus pharmaceutical vs Pharmaceutical alone | 1.45 (1.28–1.61)* | |
| Allodynia | 0.0984 | |
| Yes vs. no | 1.06 (0.95–1.19) | |
| Maybe vs. No | 0.68 (0.45–1.02) | |
| Yes vs. maybe | 1.57 (1.04–2.36)* | |
| Anxiety symptoms at consultation visit | 1.17 (1.05–1.30)* | 0.0066* |
| Feeling depressed at consultation visit | 1.28 (1.13–1.47)* | 0.0004* |
| Quantity of liquid intake reported as at least 48 ounces/day at visit A | 1.13 (1.01–1.26)* | 0.0439* |
| Reporting skipping meals at visit A | 1.05 (0.94–1.17) | 0.456 |
| Negative Predictors of Clinical Worsening | OR (95% CI) | P Value |
| Chronic migraine at visit A | 0.62 (0.55–0.69)* | <0.0001* |
| Medication overuse at visit A | 0.50 (0.39–0.65)* | <0.0001* |
| Visit B in the summer | 0.69 (0.60–0.78)* | <0.0001* |
| Headache frequency at visit A | 0.94 (0.93–0.94)* | <0.0001* |
| Headache severity at visit A | 0.96 (0.94–0.98)* | 0.0018* |
| PedMIDAS/MIDAS grade at visit A | 0.0049* | |
| Grade 2 vs. 1 | 0.90 (0.80–1.01) | |
| Grade 3 vs. 1 | 0.82 (0.69–0.96)* | |
| Grade 4 vs. 1 | 0.77 (0.66–0.89)* | |
| Grade 3 vs. 2 | 0.91 (0.76–1.09) | |
| Grade 4 vs. 2 | 0.85 (0.73–1.01) | |
| Grade 4 vs. 3 | 0.94 (0.78–1.15) | |
| Exercise reported as at least 3 times/week at visit A | 0.95 (0.84–1.07) | 0.494 |
| Quantity of sleep reported as at least 8 hours/day at visit A | 0.98 (0.87–1.10) | 0.828 |
| History of caffeine intake at visit A | 0.90 (0.81–1.00) | 0.0654 |
*
Indicates statistical significance at adjusted p<0.05 level (adjusted p value after correcting for multiple hypothesis testing)